TY - JOUR
T1 - Demonstration of antibiofilm and antifungal efficacy of chitosan against candidal biofilms, using an in vivo central venous catheter model
AU - Martinez, Mluis R.
AU - Mihu, Mircea Radu
AU - Tar, Moses
AU - Cordero, Radames J.B.
AU - Han, George
AU - Friedman, Adam J.
AU - Friedman, Joel M.
AU - Nosanchuk, Joshua D.
N1 - Funding Information:
Received 28 April 2009; accepted 22 July 2009; electronically published 23 March 2010. Potential conflicts of interest: none reported. Financial support: National Institutes of Health (grant T32AI007506-11A1 to L.R.M. and grant AI056070-01A2 to J.D.N.); Department of Defense (grant DAMD17-03-1-0127 to J.M.F. and A.J.F.); Orlando Dermatology and Aesthetic Conference (grant to A.J.F.). a L.R.M. and M.R.M. contributed equally to this work. Reprints or correspondence: Luis R. Martinez, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461 (lmartine@aecom.yu.edu).
PY - 2010/5/1
Y1 - 2010/5/1
N2 - Candida species are a major cause of catheter infections. Using a central venous catheter Candida albicans biofilm model, we demonstrated that chitosan, a polymer isolated from crustacean exoskeletons, inhibits candidal biofilm formation in vivo. Furthermore, chitosan statistically significantly decreased both the metabolic activity of the biofilms and the cell viability of C. albicans and Candida parapsilosis biofilms in vitro. In addition, confocal and scanning electron microscopic examination demonstrated that chitosan penetrates candidal biofilms and damages fungal cells. Importantly, the concentrations of chitosan that were used to evaluate fungal biofilm susceptibility were not toxic to human endothelial cells. Chitosan should be considered for the prevention or treatment of fungal biofilms on central venous catheters and perhaps other medical devices.
AB - Candida species are a major cause of catheter infections. Using a central venous catheter Candida albicans biofilm model, we demonstrated that chitosan, a polymer isolated from crustacean exoskeletons, inhibits candidal biofilm formation in vivo. Furthermore, chitosan statistically significantly decreased both the metabolic activity of the biofilms and the cell viability of C. albicans and Candida parapsilosis biofilms in vitro. In addition, confocal and scanning electron microscopic examination demonstrated that chitosan penetrates candidal biofilms and damages fungal cells. Importantly, the concentrations of chitosan that were used to evaluate fungal biofilm susceptibility were not toxic to human endothelial cells. Chitosan should be considered for the prevention or treatment of fungal biofilms on central venous catheters and perhaps other medical devices.
UR - http://www.scopus.com/inward/record.url?scp=77950949287&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77950949287&partnerID=8YFLogxK
U2 - 10.1086/651558
DO - 10.1086/651558
M3 - Article
C2 - 20331379
AN - SCOPUS:77950949287
SN - 0022-1899
VL - 201
SP - 1436
EP - 1440
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 9
ER -